Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Fibrin and chymotrypsin-like protease substrates" does not refer to a specific biological target, receptor, or enzyme. Instead, it describes a combination of substrates used in biochemical assays to characterize the activity of fibrinolytic enzymes and chymotrypsin-like serine proteases. Fibrin is the primary protein component of blood clots, and its degradation (fibrinolysis) is a key physiological process. Chymotrypsin-like protease substrates, such as N-Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SAApNA), are synthetic peptides used to measure the catalytic efficiency of enzymes that cleave peptide bonds adjacent to large hydrophobic residues. Many fibrinolytic enzymes, particularly those isolated from fungi (e.g., Nattokinase, Lumbrokinase, and mushroom-derived proteases), are characterized by their dual ability to degrade fibrin and act upon chymotrypsin-like substrates. Consequently, this name likely originates from assay descriptions in chemical databases rather than representing a canonical protein target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibrin and chymotrypsin-like protease substrates.